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Abstract
Aims The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection frac-
tion (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and
atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown.
Methods and results We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular
(LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and
ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were signiﬁcantly greater in
HFpEF [0.96 pg/mL; 95% conﬁdence interval (CI) = 0.83–1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95%
CI = 0.6–0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a signiﬁcant predictor
of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a
greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence
of HFpEF (standardized β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = 0.23; 95%
CI = 0.42 to 0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95%
CI = 0.09–0.43; P = 0.003) and with an increased risk of death or HF admissions during follow-up (hazard ratio = 1.61; 95%
CI = 1.13–2.29; P = 0.008).
Conclusions Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher
AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These ﬁndings may indicate that
a relative deﬁciency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to
AVP excess.
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Introduction
The arginine vasopressin (AVP) pathway is important in the
regulation of sodium and water metabolism, as well as vas-
cular homeostasis.1 Arginine vasopressin exerts a wide vari-
ety of effects on the heart, vascular smooth muscle,
vascular endothelium, platelets, and kidneys. V1a receptors
mediate vasoconstriction, platelet aggregation, myocardial
hypertrophy, and ﬁbrosis, whereas activation of V2 recep-
tors in renal collecting ducts mediates the antidiuretic ef-
fects of AVP.2
Excessive activation of the AVP pathway has been consid-
ered a maladaptive response to heart failure (HF), contribut-
ing to volume retention.1 Circulating levels of AVP have been
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studied in HF with reduced ejection fraction (HFrEF)3 and
shown to correlate with the severity of left ventricular (LV)
dysfunction4 and with clinical outcomes.5 However, little data
are available regarding the role of AVP in HF with preserved
ejection fraction (HFpEF). Recent studies demonstrated
increased circulating copeptin levels (a surrogate for AVP
release) in subjects with HFpEF.6,7 However, the correlates
of increased AVP levels in HFpEF are not well understood.
In particular, whether increased AVP levels are associated
with LV remodelling in HFpEF and HFrEF is unknown.
Similarly, little is known about the association between AVP
levels and atrial natriuretic peptide (ANP) levels, which are
released in response to increased atrial stretch and inhibit
AVP release.8
In this study, we aimed to (i) compare levels of plasma AVP
between subjects with HFpEF and HFrEF and subjects without
HF; (ii) assess the association between AVP, ANP levels, and
left atrial (LA) volume; (iii) assess the association between
AVP and LV remodelling; and (iv) assess the association be-
tween AVP and the risk of incident cardiovascular death or
HF admission.
Methods
We prospectively enrolled a convenience sample of patients
referred for a cardiac magnetic resonance imaging (MRI)
study at the Corporal Michael J. Crescenz VA Medical Center.
The protocol was approved by the Philadelphia VA Medical
Center Institutional Review Board, and all subjects provided
written informed consent.
Heart failure with reduced ejection fraction was deﬁned
as a symptomatic HF in the presence of an LV ejection frac-
tion (LVEF) < 50%. Heart failure with preserved ejection
fraction was deﬁned as (i) New York Heart Association Class
II–IV symptoms consistent with HF, in the absence of signif-
icant aortic or mitral stenosis; (ii) LVEF > 50%; and (iii) a
mitral E wave to annular e0 ratio > 14,9 or at least two of
the following: (a) a mitral E wave to annular e0 ratio > 8;
(b) treatment with a loop diuretic for control of HF symp-
toms; (c) LA volume index > 34 mL/m2 of body surface
area; (d) N-terminal pro B-type natriuretic peptide
level > 200 pg/mL; and (e) LV mass index > 149 g/m2 in
men and 122 g/m2 in women (measured by cardiac MRI).
Subjects without HF had an LVEF > 50%, no signiﬁcant
valvular disease, and no symptoms and signs consistent
with HF.
Key exclusion criteria were as follows: (i) claustrophobia;
(ii) presence of metallic objects or implanted medical devices
in body; (iii) conditions that could make the interpretation of
MRI less accurate and/or unreliable (i.e. arrhythmia such as
atrial ﬁbrillation affecting cardiac gating and inability to hold
breath for the cardiac MRI acquisitions); and (iv) known
inﬁltrative or hypertrophic cardiomyopathy, or extra-cardiac
amyloidosis or sarcoidosis.
Measurement of serum arginine vasopressin and
atrial natriuretic peptide
Venous plasma samples were obtained at the time of enrol-
ment and stored at 80°C for batch analysis. Arginine vaso-
pressin and ANP were measured with enzyme-linked
immunosorbent assay technique (Cayman Chemical, Ann
Arbor, MI, USA).
Measurement of central blood pressure
We measured central blood pressure via carotid arterial
tonometry performed in the supine position immediately
after the MRI, using a high-ﬁdelity Millar applanation
tonometer (SPT-301; Millar Instruments, Houston, TX, USA)
and a dedicated acquisition platform (Sphygmocor device;
Atcor Medical, Sydney, Australia). This approach does not
require the use of a generalized transfer function, because
the carotid pressure waveform is a direct surrogate of aortic
pressure.
Cardiac magnetic resonance imaging
We measured LV mass and volume and LA volume, using a
1.5 Tesla whole-body MRI scanner (Avanto or Espree;
Siemens, Malvern, PA, USA) equipped with a phase-array
cardiac coil.
Left ventricular volumes (end-diastolic and end-systolic
volumes) and function (ejection fraction) were measured
using steady-state free-precession cine imaging. Typical
acquisition parameters were repetition time (TR) = 30.6 ms;
echo time (TE) = 1.3 ms; slice thickness = 8 mm; phases = 30;
parallel image (IPAT) factor = 2; and matrix size = 192 × 192.
CMR42 software (Circle CVI, Calgary, AB, Canada) was uti-
lized to manually trace the LV short-axis cine images at
end of diastole and systole. Left ventricular mass was calcu-
lated as the difference between epicardial and endocardial
volumes, multiplied by the myocardial density. Left ventricu-
lar mass was normalized for body height raised to the allo-
metric power of 1.7.10 Left atrial volume was calculated by
averaging the volumes measured end-systole by manually
tracing the LA endocardial border in the apical two-chamber
and four-chamber views.
Statistical methods
Continuous and categorical variables were compared be-
tween the groups using analysis of variance and chi-squared
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tests, respectively. Multivariable linear regression models
were utilized to assess HFpEF and HFrEF as predictors of
AVP levels, with and without adjusting for potential
confounders. When required, Box–Cox transformation was
applied to normalize regression model residuals. A second
set of multivariable linear regression models were utilized
to assess the association between ANP and AVP.
Multivariable linear regression was also utilized to assess
whether AVP was associated with LV mass index. We present
standardized regression coefﬁcients for easier comparison of
the magnitude of the effect of various predictors on the
dependent variable in regression models. The association
between AVP levels and the risk of a composite endpoint of
incident hospitalized HF or cardiovascular death was assessed
with proportional hazards (Cox) regression. All tests were
two-tailed. Statistical signiﬁcance was deﬁned as a
P-value ≤ 0.05. We used SPSS v24 for Mac (IBM, Chicago,
IL, USA) and Matlab v2016b (The Mathworks; Natick, MA,
USA) to perform statistical analyses.
Results
Baseline characteristics of our participants with HFpEF and
HFrEF and no HF are presented and compared in Table 1.
Association of arginine vasopressin and heart
failure with preserved ejection fraction
Figure 1 shows mean AVP levels in patients without
HF, HFpEF, and HFrEF. There were signiﬁcant between-
group differences in AVP levels (analysis of variance
P = 0.0002). Arginine vasopressin levels were signiﬁcantly
greater in HFpEF [0.96 pg/mL; 95% conﬁdence interval
(CI) = 0.83–1.1 pg/mL] compared with controls (0.69 pg/
mL; 95% CI = 0.6–0.77 pg/mL; P for pairwise compari-
son = 0.0003). In post hoc pairwise comparisons, AVP
levels among subjects with HFrEF (0.73 pg/mL; 95%
Table 1 General characteristics of study participants
No HF (n = 71) HFrEF (n = 25) HFpEF (n = 28) P-value
Age 61.55 (58.97 to 64.13) 65.2 (60.85 to 69.55) 63.61 (59.49 to 67.72) 0.34
Male sex 64 (90.14%) 24 (96.00%) 24 (85.71%) 0.45
Race/ethnicity
White 34 (47.89%) 14 (56.00%) 8 (28.57%) 0.10
African American 33 (46.48%) 11 (44.00%) 20 (71.43%) 0.057
Other 4 (5.63%) 0 (0.00%) 0 (0.00%) 0.21
Body mass index (kg/m2) 30.3 (28.84 to 31.77) 29.53 (27.07 to 32) 35.7 (33.36 to 38.03) 0.0003
Hypertension 59 (83.10%) 21 (84.00%) 27 (96.43%) 0.21
Coronary artery disease 19 (26.76%) 21 (84.00%) 10 (35.71%) <0.0001
Diabetes mellitus 40 (56.34%) 14 (56.00%) 22 (78.57%) 0.11
History of atrial ﬁbrillation 2 (2.82%) 1 (4.00%) 1 (3.57%) 0.95
History of CVA or TIA 10 (14.08%) 7 (28.00%) 4 (14.29%) 0.26
Peripheral vascular disease 6 (8.45%) 4 (16.00%) 7 (25.00%) 0.09
Current smoker 15 (21.13%) 8 (32.00%) 5 (17.86%) 0.42
Beta-blocker use 29 (40.85%) 22 (88.00%) 22 (78.57%) <0.0001
ACE inhibitor use 36 (50.70%) 18 (72.00%) 17 (60.71%) 0.17
ARB use 5 (7.04%) 2 (8.00%) 6 (21.43%) 0.10
Furosemide use 2 (2.82%) 14 (56.00%) 16 (57.14%) <0.0001
Spironolactone use 1 (1.41%) 2 (8.00%) 1 (3.57%) 0.27
Calcium channel blocker use 25 (35.21%) 6 (24.00%) 11 (39.29%) 0.47
Thiazide use 19 (26.76%) 7 (28.00%) 10 (35.71%) 0.67
eGFR (mL/m2) 83.88 (78.04 to 89.73) 79.76 (69.91 to 89.61) 79.32 (70.02 to 88.63) 0.63
Systolic BP (mmHg) 144.5 (140 to 149.1) 141 (133.3 to 148.7) 154.5 (147.2 to 161.8) 0.029
Diastolic BP (mmHg) 83.61 (81 to 86.3) 80.2 (75.8 to 84.7) 87.5 (83.3 to 91.7) 0.069
Central systolic BP (mmHg) 136.7 (131.29 to 142.1) 136.6 (127.7 to 145.6) 150.8 (141.8 to 159.8) 0.026
NYHA Class III–IV 0 1 (4.17%) 1 (3.57%) 0.25
LV EDV (mL) 145 (132.8 to 157.2) 231.9 (211.4 to 252.5) 170.3 (150.8 to 189.7) <0.0001
LV mass (g) 145.8 (135.2 to 156.4) 186.6 (168.7 to 204.5) 182 (165.0 to 198.9) <0.0001
LVEF (%) 60.07 (57.79 to 62.34) 35.48 (31.65 to 39.32) 63.31 (59.69 to 66.93) <0.0001
LV mass index (g/m1.7) 56.29 (52.23 to 60.36) 70.82 (63.96 to 77.68) 71.46 (64.98 to 77.94) <0.0001
LVEDV index (mL/m2) 48.81 (44.8 to 52.83) 77.14 (70.37 to 83.91) 57.81 (51.42 to 64.21) <0.0001
LA volume (mL) 59.9 (52.8 to 67) 79.1 (61.9 to 96.3) 77 (62.3 to 91.6) 0.013
LA volume index (mL/m2) 28.3 (25 to 31.7) 36.8 (28.9 to 44.6) 33.9 (27.6 to 40.3) 0.041
Mitral inﬂow A wave velocity (cm/s) 74.1 (68.6 to 79.5) 61.9 (52.8 to 71) 72.3 (64.5 to 80.1) 0.08
Mitral inﬂow E wave velocity (cm/s) 69.3 (63.1 to 75.6) 65.6 (55.1 to 76) 82.9 (74.2 to 91.7) 0.02
Mitral inﬂow E wave deceleration time (ms) 214 (195 to 233) 214 (181 to 247) 210 (182 to 238) 0.98
E/e0 9.6 (8.3 to 10.8) 11.7 (9.1 to 14.3) 12.4 (10.1 to 14.7) 0.04
ACE, angiotensin convertase enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CVA, cerebrovascular accident; E/e0, mitral
inﬂow to mitral annular tissue velocity ratio; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; HFpEF, heart failure with pre-
served ejection fraction; HFrEF, heart failure with reduced ejection fraction; LA, left atrial; LV, left ventricular; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; TIA, transient ischaemic attack.
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CI = 0.59–0.88 pg/mL) did not signiﬁcantly differ from any
of the other two groups.
We also assessed the presence of HFpEF or HFrEF as pre-
dictors of AVP levels in unadjusted and adjusted linear regres-
sion models. In unadjusted analyses, the presence of HFpEF
(standardized β = 0.31; 95% CI = 0.13–0.48; P = 0.0001) was
associated with higher AVP levels. In a multivariable linear
regression model adjusted for age, sex, race, systolic
blood pressure, diabetes mellitus, the use of angiotensin
convertase enzyme inhibitors, angiotensin receptor blockers,
furosemide, spironolactone, thiazide diuretics, calcium chan-
nel blockers, beta-blockers, and estimated glomerular ﬁltra-
tion rate, the presence of HFpEF was independently
associated with higher AVP levels (standardized β = 0.27;
95% CI = 0.04–0.5; P = 0.025).
Atrial natriuretic peptides and left atrial volume:
association with arginine vasopressin
Plasma ANP was negatively associated with AVP (standardized
β = 0.25; 95% CI = 0.43 to 0.065; P = 0.008). Figure 2
(bottom left panel) shows mean ANP levels among subjects
above and below the median value of AVP (0.64 pg/mL). Atrial
natriuretic peptide levels were 828 (95% CI = 706–950) and
588 (95% CI = 501–674) pg/mL in subjects below and above
the median value of AVP, respectively (P = 0.008). In a linear
regression model that included ANP and LA volume, LA
volume was positively associated (standardized β = 0.21; 95%
CI = 0.03–0.40; P = 0.022), whereas ANP was negatively
associated (standardized β = 0.19; 95% CI = 0.37 to
0.01; P = 0.04) with AVP levels (Figure 2, top panel). The
ANP/LA volume ratio was higher (12.3; 95% CI = 9.6–15.1) in
subjects below vs. those above (8.5; 95% CI = 6.6–10.4) the
median value of AVP (P = 0.011; Figure 2; bottom right panel).
In a multivariable model that adjusted for HF group mem-
bership, race, sex, age, systolic blood pressure, diabetes
mellitus, the use of angiotensin convertase enzyme inhibi-
tors, angiotensin receptor blockers, furosemide, estimated
glomerular ﬁltration rate, and New York Heart Association
Class III–IV (Table 2), the two independent correlates of a
higher AVP were the presence of HFpEF (standardized
β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA vol-
ume ratio (standardized β = 0.23; 95% CI = 0.42 to 0.04;
P = 0.0196).
Association of arginine vasopressin levels and left
ventricular hypertrophy
In unadjusted analyses, AVP levels were directly associated
with LV mass (standardized β = 0.29; 95% CI = 0.12–0.46;
P = 0.001, Figure 3, upper panel). In a model that adjusted
for HF status, age, sex, race, glomerular ﬁltration rate and
central systolic blood pressure (Figure 3, lower panel), AVP
was a signiﬁcant independent predictor of LV mass (standard-
ized β = 0.24; 95% CI = 0.07–0.40; P = 0.005). Similarly, after
further adjustment for the use of angiotensin convertase en-
zyme inhibitors, angiotensin receptor blockers, furosemide,
spironolactone, thiazide diuretics, calcium channel blockers,
and beta-blockers, AVP continued to be directly associated
with greater LV mass index (standardized β = 0.26; 95%
CI = 0.09–0.43; P = 0.003).
Arginine vasopressin as a predictor of outcomes
During a median follow-up of 1507 days (~4.12 years), 15 sub-
jects had an HF admission, and 10 died of cardiovascular
causes. Figure 4 shows the Kaplan–Meier event-free survival
curves for subjects stratiﬁed by the median value of AVP. Sur-
vival was signiﬁcantly lower in subjects with higher AVP. In a
proportional hazards regression model, AVP was a signiﬁcant
predictor of an increased risk of incident cardiovascular death
or HF admission [standardized hazard ratio (HR) = 1.61; 95%
CI = 1.13–2.29; P = 0.008]. Similarly, AVP predicted the end-
point after adjustment for age, gender, and HF group mem-
bership (standardized HR = 1.65; 95% CI = 1.10–2.49;
P = 0.016). The association between AVP and incident cardio-
vascular death or hospitalized HF was also independent of LA
volume index, LV mass, and ANP (standardized HR = 1.82;
95% CI = 1.12–2.96; P = 0.015). In an analysis that included
only subjects with HF (HFpEF or HFrEF), AVP predicted
Figure 1 Comparison of arginine vasopressin (AVP) levels between sub-
jects without heart failure (HF), subjects with heart failure with reduced
ejection fraction (HFrEF), and heart failure with preserved ejection frac-
tion (HFpEF).
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incident cardiovascular death or HF admissions (standardized
HR = 1.72; 95% CI = 1.09–2.72; P = 0.021).
Discussion
In this study, we report that HFpEF is associated with
increased plasma AVP, even after adjustment for potential
confounders. We report, for the ﬁrst time, that AVP levels
are independently associated with the combination of
greater LA volume and paradoxically low ANP levels. This
ﬁnding is consistent with the physiological regulation of
AVP by ANP demonstrated in animal models and raise the
hypothesis that atrial natriuretic peptide deﬁciency in the set-
ting of increased LA pressure is related to AVP excess, which
should be tested in future studies. We demonstrate that AVP
independently correlates with LV hypertrophy measured by
MRI. Finally, we show that greater AVP levels are associated
with an increased risk of adverse outcomes, independent of
ANP, LA volume, and LV mass. Our ﬁndings contribute to
Figure 2 Association between atrial natriuretic peptide (ANP) and left atrial (LA) volume vs. arginine vasopressin (AVP). High AVP was associated with
lower ANP levels. The bottom left panel shows mean ANP levels in subjects above vs. below the median value of AVP. In a linear regression model, a
low ANP and a higher LA volume were independent predictors of AVP (top panel). Subjects with AVP levels above the median value demonstrated
lower ANP/LA volume ratios (right bottom panel).
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Table 2 Correlates of AVP in multivariable linear regression
Standardized
estimate
95% CI,
lower
bound
95% CI,
upper
bound P-value
ANP/LA volume
ratio
0.23 0.42 0.04 0.0196
HFpEF 0.32 0.09 0.56 0.0073
HFrEF 0.01 0.21 0.23 0.8985
Age 0.10 0.31 0.12 0.3670
Male sex 0.16 0.03 0.35 0.1022
African American
ethnicity
0.16 0.03 0.35 0.1036
Systolic blood
pressure
0.06 0.28 0.15 0.5567
Diabetes mellitus 0.12 0.33 0.08 0.2268
ACE inhibitor use 0.06 0.14 0.26 0.5292
ARB use 0.05 0.26 0.16 0.6208
Furosemide use 0.16 0.08 0.40 0.1868
eGFR 0.05 0.25 0.15 0.6338
NYHA Class III–IV 0.12 0.31 0.07 0.22421
ACE, angiotensin convertase enzyme; ANP, atrial natriuretic
peptide; ARB, angiotensin receptor blocker; AVP, arginine
vasopressin; CI, conﬁdence interval; eGFR, estimated glomerular
ﬁltration rate; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; LA, left atrial;
NYHA, New York Heart Association.
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our understanding of the correlates of circulating AVP excess
and its clinical relevance in human HF.
Arginine vasopressin in heart failure
Arginine vasopressin is a nonapeptide synthesized by the hy-
pothalamus, and it is released into the circulation from the
neurohypophysis in response to various osmotic and non-
osmotic stimuli (intravascular hypovolaemia).2 Initial studies
in patients with HFrEF and asymptomatic LV dysfunction re-
ported that AVP levels are inappropriately elevated in these
conditions (in response to non-osmotic stimuli).3,4,11 Secre-
tion of AVP can lead to deleterious effects in HF through its
vasoconstrictive (V1a receptors) and free water retaining
properties (V2 receptors), as well as through its hypertrophy
and ﬁbrosis promoting effects on the myocardium (V1a
receptors) leading to adverse cardiac remodelling.1 Whereas
great attention has been placed on V2-related effects on
hyponatraemia in advanced HF, much less is known about
the role of vascular and myocardial V1a effects. Finally, little
is known about the relationship between ANP and AVP levels,
despite its well-known physiological cross-regulation.8
To the best of our knowledge, no prior study has reported
the comparative association of plasma AVP with HFpEF vs.
HFrEF. We observed that in adjusted models, mean levels of
AVP were signiﬁcantly higher in HFpEF as compared with
HFrEF and the control group. Of note, average AVP levels in
our participants with HFrEF were lower than those previously
reported in the older studies,3,4 However, more recent
studies have reported similar results as ours.5 In the Efﬁcacy
of Vasopressin Antagonism in Heart Failure Outcome Study
with Tolvaptan (EVEREST), 59% of the participants had AVP
levels below the lower detection limit of the assay, and
another 19% had levels within normal range.5 This difference
might be related to (i) increased utilization of guideline
directed medial therapy in recent studies12 and (ii)
differences in assay sensitivity.13 Copeptin is the C-terminal
peptide of the precursor protein to AVP and is secreted in
equimolar amounts as AVP in the circulation.14 Mainly due
to the short half-life of AVP, copeptin has been utilized as a
surrogate marker of AVP activity in recent investigations.6,7
Data from these investigations suggest that higher copeptin
levels are associated with an increased risk of adverse out-
comes in both unselected HF6,7 and selected samples with
HFpEF.15 Contrary to our ﬁndings (higher AVP in HFpEF com-
pared with HFrEF), Loncar et al.16 reported that copeptin
levels were signiﬁcantly higher in HFrEF compared with
HFpEF. However, their study enrolled participants with recent
HF exacerbation, which might have led to a higher degree of
Figure 3 Predictors of left ventricular (LV) mass by linear regression. The
top panel shows an unadjusted model showing the association between
arginine vasopressin (AVP) and LV mass. The bottom panel shows a mul-
tivariable model demonstrating independent correlates of LV mass. BP,
blood pressure; eGFR, estimated glomerular ﬁltration rate; HFpEF, heart
failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction.
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HFrEF
Age
Male sex
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Figure 4 Left: Kaplan–Meier survival curves for cardiovascular death or heart failure hospitalization among subjects stratiﬁed according to the median
value of arginine vasopressin (AVP). Dashed red lines represent 95% conﬁdence interval (CI).
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neurohormonal activation (and AVP levels) when compared
with the participants with chronic HF enrolled in our study.
Arginine vasopressin excess and left ventricular
mass
Prior studies in animal models have demonstrated that the
activation of V1a receptors by AVP leads to structural
changes in cardiac myocytes and ﬁbroblasts leading to an
increase in myocardial mass (LV hypertrophy).17,18 Tozawa
et al.19 reported that in spontaneously hypertensive rats
treated with an angiotensin convertase enzyme inhibitor
(delapril), there was a positive direct association between
LV mass and AVP levels. In a cross-sectional analysis of 706
middle-aged participants without cardiovascular comorbidi-
ties, Bhandari et al.20 reported a weak direct correlation of
copeptin levels with indexed LV mass. In a prospective inves-
tigation of middle-aged participants, Strand et al.21 demon-
strated that higher baseline AVP levels predicted the
development of LV hypertrophy at 20 years of follow-up in
17 participants who were diagnosed with hypertension in
interim. We hereby report a direct independent association
between AVP levels and LV mass determined with cardiac
MRI, independent of the presence or absence of HF and
multiple potential confounders, including renal function and
central systolic blood pressure. Taken together, available
animal studies and human data support a role for AVP in
the development of LV hypertrophy, an important cardiovas-
cular phenotype involved in the pathogenesis of HF.22
Arginine vasopressin, atrial natriuretic peptide,
and left atrial volume
Despite the importance of AVP and its role in hyponatraemia
in advanced HF, little is known about the non-osmotic trig-
gers for its release in humans with and without HF. A role
for baroreceptor desensitization has been proposed as a
cause for dysregulated AVP release.23 However, human stud-
ies assessing the association between the ANP axis and AVP
levels are scarce. Atrial natriuretic peptide, a member of
the natriuretic peptide family, is released in response to atrial
stretch and exerts a variety of biological effects such as natri-
uresis, vasodilation, and inhibition of renin–angiotensin–
aldosterone pathway.24 Animal models have also established
an inhibitory role for ANP on AVP release.25 Vascular and in-
tracerebral administration of ANP inhibits the release of
AVP,8 and ANP binding sites after systemic administration of
ANP have been identiﬁed in the posterior pituitary.25 Inter-
estingly, in our study, LA enlargement with paradoxically
low ANP levels was associated with increased AVP levels.
Although physiological considerations from animal models
suggest that a deﬁcient ANP axis may causally contribute to
such excess, further studies are required to establish this
mechanism in human HF and to determine whether strate-
gies aimed at enhancing natriuretic peptide activity blunt
AVP excess and its deleterious consequences. Our ﬁndings
are consistent with the recently proposed paradigm that a
deﬁciency of ANP and/or increased target organ resistance
to ANP actions contribute to LV remodelling26 and HF.27
Our study also demonstrates that increased AVP levels are
associated with an increased risk of incident cardiovascular
death or hospitalized HF. This association was highly signiﬁ-
cant and was independent of ANP levels, LV mass, and LV
enlargement measured by cardiac MRI, supporting the clini-
cal importance of AVP.
Our study should be interpreted in context of its strengths
and limitations. We utilized cardiac MRI, which provides
highly accurate measurements of chamber volumes and
function. However, we acknowledge that our study has limi-
tations. Our ﬁndings are observational in nature, and this
cannot prove causal associations. Although most analyses
were based on well-established quantitative traits, our sam-
ple size and the number of prospective events during
follow-up was relatively small, and thus, only limited
adjustments were possible to avoid overﬁtting of propor-
tional hazards models; the low number of events also pre-
cluded stratiﬁed analyses by HF subtype. Residual
confounding could still be present, and larger future studies
should study this further. Lastly, we utilized convenience sam-
pling of subjects referred for a cardiac MRI study at a Veteran
Affairs Medical Center. Thus, the majority of the participants
were male and may not be representative of AVP levels seen
in unselected HF populations. We also applied various
exclusion criteria. An important exclusion criterion was atrial
ﬁbrillation (because atrial ﬁbrillation complicates measure-
ments of LV mass by segmented cine MRI). Therefore,
extrapolation of our ﬁndings to patients with advanced atrial
disease and/or atrial arrhythmia cannot be made. We did not
assess the potential role of the sympathetic nervous system,
which is physiologically linked to AVP secretion and subject
to inhibition by ANP. The interactions between AVP, ANP,
and the sympathetic nervous system in HF (particularly
HFPEF) should be the focus of future research. Our
population exhibited relatively favourable outcomes, and
our results may not extrapolate to patients with more ad-
vanced disease.
Conclusions
Increased plasma AVP is seen in subjects with HFpEF, even af-
ter adjustment for potential confounders. Arginine vasopres-
sin levels are independently associated with a greater LA
volume and also paradoxically, with lower ANP levels. These
ﬁndings are consistent with the known inhibitory effect of
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ANP on AVP secretion. High plasma AVP was independently
associated with LV mass measured by cardiac MRI. High
AVP was predictive of an increased risk of cardiovascular
death and HF admissions, independently of LV mass, LA vol-
ume, and ANP levels. Our ﬁndings demonstrate the clinical
importance of AVP in HFpEF and suggest that a relative deﬁ-
ciency of ANP in the setting of increased LA pressure is asso-
ciated with AVP excess. Further studies are required to
establish whether this association is causal and to assess
whether strategies aimed at potentiating the ANP axis may
ameliorate AVP excess and its deleterious effects.
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